Affordable Access

deepdyve-link
Publisher Website

Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea.

Authors
  • Lee, Ji Yun1
  • Lee, Ju-Hyun1
  • Lee, Heeyoung2
  • Kang, Beodeul1
  • Kim, Ji-Won1
  • Kim, Se Hyun1
  • Lee, Jeong-Ok1
  • Kim, Jin Won1
  • Kim, Yu Jung1
  • Lee, Keun-Wook1
  • Kim, Jee Hyun1
  • Choi, Hyoung Soo3
  • Lee, Jong Seok1
  • Bang, Soo-Mee4
  • 1 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. , (North Korea)
  • 2 Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. , (North Korea)
  • 3 Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. , (North Korea)
  • 4 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: [email protected] , (North Korea)
Type
Published Article
Journal
Thrombosis research
Publication Date
Jul 01, 2017
Volume
155
Pages
86–91
Identifiers
DOI: 10.1016/j.thromres.2017.05.010
PMID: 28525829
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The epidemiology of immune thrombocytopenia (ITP) is not well characterized in an Asian population. From July 2010 to June 2014, ITP patients were identified using the Korean Health Insurance Review and Assessment Service database. The overall incidence rate of ITP was 5.3 per 100,000 person-years (95% CI: 5.1-5.5). The overall incidence rate ratios of children under 15years old to adults and females to males were 3.8 (95% CI: 3.7-3.9) and 1.3 (95% CI: 1.2-1.4), respectively. Of the total 10,814 patients, 3388 patients (31%) needed treatment for ITP; of these, 54% continued treatment for more than three months. First-line therapy consisted of corticosteroids (CS) in 42%, immunoglobulin (IVIg) in 35%, CS with IVIg in 19%, and other immunosuppressive agents (ISA) in 4%. Among treated patients, 75% of adults and 33% of children continued treatment for more than three months. After three months, the most frequently used drug was CS alone in 63% of patients. Only 104 patients underwent splenectomy; of these, 51% received salvage treatment after a median of one month after surgery (range: 0-27). The proportion of patients who received platelet transfusions of 12units or more per month for at least two consecutive months was significantly higher among patients treated for more than three months compared with patients who completed treatment within three months. This population-based study is the first to describe the incidence of ITP and its treatment reality for patients in Korea. Copyright © 2017 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times